Cellectar Biosciences, Inc. and Evestia Clinical have partnered for a Phase 1b study on CLR 125, a drug candidate for triple-negative breast cancer (TNBC). Evestia will provide full CRO services for the study. The collaboration leverages Evestia’s expanded capabilities and oncology expertise. A Mayo Clinic Network site has been selected as a treatment center for the trial, with Pooja Advani as lead investigator. TNBC is an aggressive subtype of breast cancer with limited treatment options, affecting approximately 12% of breast cancer diagnoses in the U.S. and disproportionately impacting younger women and those of African descent.

Evestia Clinical is a global CRO specializing in accelerating the development of life-saving therapies for biotech companies. Cellectar Biosciences focuses on developing cancer treatments, using its Phospholipid Drug Conjugate™ platform. The company’s pipeline includes iopofosine I 131, CLR 121225, and CLR 121125, targeting various solid tumors. Cellectar’s compounds have received designations from the FDA for different cancer indications. The company’s goal is to deliver targeted treatments with improved efficacy and safety.

Forward-looking statements in the news release caution that actual results may differ from predictions due to known and unknown risks related to drug discovery and development. Factors affecting outcomes include regulatory uncertainties, strategic execution, partnership opportunities, and funding challenges. Investors can find more information in Cellectar’s periodic reports filed with the Securities and Exchange Commission. For media inquiries, contact Evestia Clinical at [email protected] or reach out to Paul Bishop, Matthew Neal, or Melissa Gardiner for more information.

Read more at GlobeNewswire: Cellectar and Evestia Clinical Announce Partnership to